Clinical Response and Cytokines Production After Challenge With Different Wheat Genotypes in Patients With Not-celiac Wheat Sensitivity.

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Non-celiac gluten sensitivity (NCGS) is a condition where intestinal and extraintestinal symptoms are triggered by gluten ingestion in the absence of celiac disease and wheat allergy. Despite the great interest in NCGS, much remains unknown about the pathogenesis. Some studies seem to suggest that wheat components other than gluten (i.e. amylase/trypsine inhibitors, ATIs) can cause the symptoms, and therefore the term non-celiac wheat sensitivity (NCWS) has been proposed instead of NCGS. It is believed that this condition is worldwide increasing, due to the evolution of wheat breeding (i.e. consumption of wheats with high gluten content), and that ancient wheats are better tolerated by NCWS patients than the modern ones. Therefore, the aim of the study is to determine whether the common belief regarding the fact that ancient wheats are better tolerated by NCWS patients than the modern ones is confirmed by scientific data, and to identify the wheat kernel components triggering this pathology. The availability of wheat materials with opposite characteristics, such as the period of development (ancient vs. modern), or the technological properties (cultivars with weak glutens vs. strong gluten), or the presence/absence of specific ATIs polypeptides, will allow to define the role played by these factors. Therefore, the study has two objectives: 1) extraction and testing of total kernel proteins, in order to evaluate the inflammatory response to gluten and non-gluten proteins by peripheral blood mononuclear cells (PBMC) and immunocytes extracted by the rectal mucosa of NCWS patients and healthy control subjects, and 2) clinically testing two wheat genotypes, selected on the basis of the previous in vitro studies, showing the highest and the lowest in vitro inflammatory response, in order to verify their effect in triggering NCWS symptoms.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

⁃ All the patients will meet the recently proposed criteria:

• negative serum anti-tissue transglutaminase and antiendomysium (EmA) immunoglobulin (Ig)A and IgG antibodies

• absence of intestinal villous atrophy

• IgE-mediated immunoallergic tests negative to wheat (skin prick tests and/or serum specific IgE detection)

• follow-up duration \>12 months after the initial diagnosis

• at least two outpatient visits during the follow-up period.

⁃ Adjunctive criteria adopted in our patients will be:

• resolution of the gastrointestinal symptoms on a standard elimination diet, without wheat, cow's milk, egg, tomato, chocolate, or other food(s) causing self-reported symptoms

• symptom reappearance on DBPC wheat challenge, performed as described previously. As in previous studies, DBPC cow's milk protein challenge and other open food challenges will be also performed.

Locations
Other Locations
Italy
Department of Internal Medicine, University Hospital of Palermo
RECRUITING
Palermo
Department of Internal Medicine, Giovanni Paolo II Hospital of Sciacca
RECRUITING
Sciacca
Contact Information
Primary
Antonio Carroccio, PhD
acarroccio@hotmail.com
+390916552884
Backup
Pasquale Mansueto, MD
pasquale.mansueto@unipa.it
+390916552884
Time Frame
Start Date: 2017-01-01
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 50
Treatments
Active_comparator: Active Comparator 1
Wheat flour with high inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
Active_comparator: Active Comparator 2
Wheat flour with low inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
Placebo_comparator: Placebo 1
Placebo (xylose) will be administered blindly versus wheat flour with high inflammatory response for 15 days in NCWS patients.
Placebo_comparator: Placebo 2
Placebo (xylose) will be administered blindly versus wheat flour with low inflammatory response for 15 days in NCWS patients.
Sponsors
Leads: University of Palermo

This content was sourced from clinicaltrials.gov